Showing 51–67 of 67 international scientific journals (Oncology)
| Rank | Journal Name & ISSN | Country | WoS Quartile | CAS Division | Impact Factor | Scopus SJR | H-Index | Docs/yr | Self-Citation | Publisher | Profile |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 51 | Oncology and Therapy ISSN: 2366-1070 / 2366-1089 | 🇬🇧United Kingdom | Q2 | CAS Tier 3 | 3.4 | 1.159Q2 | — | 42 | 0% | Adis, Springer Healthcare | Profile |
| 52 | Translational Lung Cancer Research ISSN: 2218-6751 | 🌐Hong Kong | Q2 | CAS Tier 3 | 3.4 | 0.987Q2 | — | 354 | 5% | Society for Translational Medicine (STM) | Profile |
| 53 | Breast Cancer Research and Treatment ISSN: 0167-6806 / 1573-7217 | 🇺🇸United States | Q2 | CAS Tier 3 | 3.3 | 1.34Q1 | 139 | 398 | 6.7% | Springer US | Profile |
| 54 | Journal of Cancer Research and Clinical Oncology ISSN: 0171-5216 / 1432-1335 | 🇩🇪Germany | Q2 | CAS Tier 3 | 3.3 | 0.954Q1 | 87 | 362 | 3.7% | Springer Berlin Heidelberg | Profile |
| 55 | Lung Cancer: Targets and Therapy ISSN: 1179-2728 | 🇬🇧United Kingdom | Q2 | CAS Tier 3 | 3.3 | — | — | 8 | N/A | Dove Medical Press | Profile |
| 56 | Blood and Lymphatic Cancer-Targets and Therapy ISSN: 1179-9889 | 🇬🇧United Kingdom | Q2 | CAS Tier 3 | 3.2 | — | — | 6 | 0% | Dove Medical Press | Profile |
| 57 | Infectious Agents and Cancer ISSN: 1750-9378 | 🇬🇧United Kingdom | Q3 | CAS Tier 3 | 3.2 | 0.92Q2 | 30 | 66 | 3.2% | BioMed Central | Profile |
| 58 | American Journal of Cancer Research ISSN: 2156-6976 | 🇺🇸United States | Q2 | CAS Tier 3 | 3.1 | — | 20 | 381 | 2.8% | E-CENTURY PUBLISHING CORP | Profile |
| 59 | Cancer Control ISSN: 1073-2748 / 1526-2359 | 🇺🇸United States | Q2 | CAS Tier 3 | 3.1 | 0.907Q1 | 66 | 133 | 4% | H. Lee Moffitt Cancer Center and Research Institute | Profile |
| 60 | Future Oncology ISSN: 1479-6694 / 1744-8301 | 🇬🇧United Kingdom | Q2 | CAS Tier 4 | 3.1 | 1.229Q1 | 60 | 390 | 3.3% | Future Medicine Ltd. | Profile |
| 61 | Journal of Immunotherapy and Precision Oncology ISSN: 2666-2345 / 2590-017X | 🌐International | Q3 | CAS Tier 4 | 3.1 | 1.37Q1 | — | 6 | N/A | Innovative Healthcare Institute | Profile |
| 62 | Cancer Epidemiology ISSN: 1877-7821 / 1877-783X | 🇬🇧United Kingdom | Q3 | CAS Tier 3 | 3 | 1.036Q2 | 68 | 144 | 4.2% | Elsevier BV | Profile |
| 63 | World Journal of Surgical Oncology ISSN: 1477-7819 | 🇬🇧United Kingdom | Q3 | CAS Tier 3 | 2.8 | 0.761Q1 | 48 | 341 | 4% | BioMed Central | Profile |
| 64 | Cancer Genomics & Proteomics ISSN: 1109-6535 / 1790-6245 | 🌐Greece | Q2 | CAS Tier 3 | 2.6 | 0.807Q2 | 32 | 61 | 11.5% | International Institute of Anticancer Research | Profile |
| 65 | Thoracic Cancer ISSN: 1759-7706 / 1759-7714 | 🇨🇳China | Q3 | CAS Tier 4 | 2.6 | 0.779Q2 | 20 | 445 | 4.3% | Blackwell Publishing Asia Pty Ltd | Profile |
| 66 | Analytical Cellular Pathology ISSN: 2210-7177 / 2210-7185 | 🇳🇱Netherlands | Q4 | CAS Tier 3 | 2.5 | 0.709Q2 | 18 | 56 | 0% | Hindawi Limited | Profile |
| 67 | Radiology and Oncology ISSN: 1318-2099 / 1581-3207 | 🌐Slovenia | Q3 | CAS Tier 3 | 2.3 | 0.641Q2 | 26 | 71 | 4.8% | Walter de Gruyter | Profile |